Contrasting Pulse Biosciences (PLSE) and Its Competitors

Pulse Biosciences (NASDAQ:PLSE) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Pulse Biosciences to related businesses based on the strength of its valuation, institutional ownership, profitability, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Pulse Biosciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-5,603.88%	-77.88%	-67.89%
Pulse Biosciences Competitors	-303.57%	-175.14%	-22.20%

Volatility & Risk

Pulse Biosciences has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Pulse Biosciences’ rivals have a beta of 2.57, indicating that their average share price is 157% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pulse Biosciences and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pulse Biosciences	$350,000.00	-$72.78 million	-42.66
Pulse Biosciences Competitors	$1.87 billion	$137.20 million	5.93

Pulse Biosciences’ rivals have higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Pulse Biosciences and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1	0	5	1	2.86
Pulse Biosciences Competitors	4295	10586	18372	832	2.46

Pulse Biosciences presently has a consensus price target of $66.60, indicating a potential upside of 29.02%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.96%. Given Pulse Biosciences’ stronger consensus rating and higher possible upside, analysts clearly believe Pulse Biosciences is more favorable than its rivals.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Pulse Biosciences beats its rivals on 7 of the 13 factors compared.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc. develops medical devices using its proprietary nanosecond pulsed field ablation (nsPFA) technology. The technology delivers very short electrical pulses intended to disrupt targeted cells without relying on heat, with the goal of limiting effects on surrounding tissue. The company is developing nsPFA applications for cardiac electrophysiology and surgical oncology, including devices for tissue ablation. Its earlier CellFX System brought the technology to dermatology for treating certain benign skin lesions, marking an initial commercial application of the platform.